Dr. Ilson on Chemotherapy in Advanced Gastric Cancer

Video

In Partnership With:

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the use of chemotherapy in advanced gastric cancer.

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the use of chemotherapy in advanced gastric cancer.

Novel agents have been evaluated in gastric cancer, says Ilson. However, chemotherapy remains a frontline standard of care in the advanced setting. Typically, regimens such as FOLFOX, which consist of a fluoropyrimidine and a platinum-based agent, are given, says Ilson.

Past research efforts have suggested that the addition of taxane chemotherapy to docetaxel, cisplatin, and 5-fluorouracil might improve patient outcomes. However, data from a large Japanese trial showed that the addition of docetaxel to fluoropyrimidine and platinum did not result in better outcomes. As such, fluoropyrimidine and platinum-based chemotherapy continues to be the standard of care, concludes Ilson.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD